CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 113 enrolled
Drug / intervention
Etanercept (genetical recombination)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01145352
NCT01145352N/ACompleted

Enbrel-JIA Use Results Survey [All-Case Surveillance]

Pfizer·observational·Posted Jun 16, 2010·Updated Sep 4, 2014

In Brief

An observational study evaluating Etanercept (genetical recombination) for Juvenile Idiopathic Arthritis. Completed, enrolled 113 participants across 1 site.

Detailed Summary

This surveillance is conducted to survey the followings under the post marketed drug utilization on the patients who are administrated ENBREL as a treatment for active polyarticular JIA. 1. Primary Occurrence status of Adverse Events; incidence of all adverse events, serious adverse events 2. Secondary Factors affecting safety and to confirm the efficacy such as DAS28.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 16, 2010
Enrollment StartJul 1, 2009
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 16.0 years ago

Interventions

Etanercept (genetical recombination)drug

All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year).